Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Alois Gratwohl, Ronald Brand, Jane Apperley, Charles Crawley, Tapani Ruutu, Paolo Corradini, Enric Carreras, Agnes Devergie, Cesare Guglielmi, Hans Jochen Kolb, Dietger Niederwieser

Research output: Contribution to journalArticle

Abstract

The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Information on the current use and results of HSCT is warranted. Data from 592 teams in 42 European countries described their use of HSCT for CML from 1990 to 2004. Outcomes were analyzed for 13,416 patients, with a median age of 36 years (range 1-71 years); 60% were male. The analysis considered three time cohorts, 1980 to 1990, 1991 to 1999 and 2000 to 2003. Survival, transplant-related mortality and relapse incidence were assessed at 20 years for the first cohort and compared at 2 years between the three cohorts. The numbers of HSCT for CML increased from 540 allogeneic HSCT in 1990 to 1,396 HSCT in 1999 and declined to 802 in 2004. One third of all patients and half of those with a low risk were alive at 20 years. Survival at 2 years has improved from 53% to 61% in the most recent years due to a reduction in transplant-related mortality from 41% to 30% in all patients and from 31% to 17% in low-risk patients. Stage, donor type, time interval, age and donor-recipient sex combination remain the main risk factors; patients with a risk score of 0 or 1 have a survival probability of 80% at 2 years. HSCT remains an important treatment option for patients with CML. The data describe the current status of this option and the outcome a patient can expect today. They provide an objective basis for decision making.

Original languageEnglish
Pages (from-to)513-521
Number of pages9
JournalHaematologica
Volume91
Issue number4
Publication statusPublished - Apr 2006

Fingerprint

Hematopoietic Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia
Transplants
Survival
Tissue Donors
Mortality
Decision Making
Recurrence
Incidence

Keywords

  • Chronic myeloid leukemia
  • Europe
  • Hematopoietic stem cell transplantation
  • Long term results
  • Outcome
  • Transplant related mortality

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006 : Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). / Gratwohl, Alois; Brand, Ronald; Apperley, Jane; Crawley, Charles; Ruutu, Tapani; Corradini, Paolo; Carreras, Enric; Devergie, Agnes; Guglielmi, Cesare; Kolb, Hans Jochen; Niederwieser, Dietger.

In: Haematologica, Vol. 91, No. 4, 04.2006, p. 513-521.

Research output: Contribution to journalArticle

Gratwohl, Alois ; Brand, Ronald ; Apperley, Jane ; Crawley, Charles ; Ruutu, Tapani ; Corradini, Paolo ; Carreras, Enric ; Devergie, Agnes ; Guglielmi, Cesare ; Kolb, Hans Jochen ; Niederwieser, Dietger. / Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006 : Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). In: Haematologica. 2006 ; Vol. 91, No. 4. pp. 513-521.
@article{aee01cc14afe40de8fff694502be3ea4,
title = "Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)",
abstract = "The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Information on the current use and results of HSCT is warranted. Data from 592 teams in 42 European countries described their use of HSCT for CML from 1990 to 2004. Outcomes were analyzed for 13,416 patients, with a median age of 36 years (range 1-71 years); 60{\%} were male. The analysis considered three time cohorts, 1980 to 1990, 1991 to 1999 and 2000 to 2003. Survival, transplant-related mortality and relapse incidence were assessed at 20 years for the first cohort and compared at 2 years between the three cohorts. The numbers of HSCT for CML increased from 540 allogeneic HSCT in 1990 to 1,396 HSCT in 1999 and declined to 802 in 2004. One third of all patients and half of those with a low risk were alive at 20 years. Survival at 2 years has improved from 53{\%} to 61{\%} in the most recent years due to a reduction in transplant-related mortality from 41{\%} to 30{\%} in all patients and from 31{\%} to 17{\%} in low-risk patients. Stage, donor type, time interval, age and donor-recipient sex combination remain the main risk factors; patients with a risk score of 0 or 1 have a survival probability of 80{\%} at 2 years. HSCT remains an important treatment option for patients with CML. The data describe the current status of this option and the outcome a patient can expect today. They provide an objective basis for decision making.",
keywords = "Chronic myeloid leukemia, Europe, Hematopoietic stem cell transplantation, Long term results, Outcome, Transplant related mortality",
author = "Alois Gratwohl and Ronald Brand and Jane Apperley and Charles Crawley and Tapani Ruutu and Paolo Corradini and Enric Carreras and Agnes Devergie and Cesare Guglielmi and Kolb, {Hans Jochen} and Dietger Niederwieser",
year = "2006",
month = "4",
language = "English",
volume = "91",
pages = "513--521",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006

T2 - Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

AU - Gratwohl, Alois

AU - Brand, Ronald

AU - Apperley, Jane

AU - Crawley, Charles

AU - Ruutu, Tapani

AU - Corradini, Paolo

AU - Carreras, Enric

AU - Devergie, Agnes

AU - Guglielmi, Cesare

AU - Kolb, Hans Jochen

AU - Niederwieser, Dietger

PY - 2006/4

Y1 - 2006/4

N2 - The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Information on the current use and results of HSCT is warranted. Data from 592 teams in 42 European countries described their use of HSCT for CML from 1990 to 2004. Outcomes were analyzed for 13,416 patients, with a median age of 36 years (range 1-71 years); 60% were male. The analysis considered three time cohorts, 1980 to 1990, 1991 to 1999 and 2000 to 2003. Survival, transplant-related mortality and relapse incidence were assessed at 20 years for the first cohort and compared at 2 years between the three cohorts. The numbers of HSCT for CML increased from 540 allogeneic HSCT in 1990 to 1,396 HSCT in 1999 and declined to 802 in 2004. One third of all patients and half of those with a low risk were alive at 20 years. Survival at 2 years has improved from 53% to 61% in the most recent years due to a reduction in transplant-related mortality from 41% to 30% in all patients and from 31% to 17% in low-risk patients. Stage, donor type, time interval, age and donor-recipient sex combination remain the main risk factors; patients with a risk score of 0 or 1 have a survival probability of 80% at 2 years. HSCT remains an important treatment option for patients with CML. The data describe the current status of this option and the outcome a patient can expect today. They provide an objective basis for decision making.

AB - The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Information on the current use and results of HSCT is warranted. Data from 592 teams in 42 European countries described their use of HSCT for CML from 1990 to 2004. Outcomes were analyzed for 13,416 patients, with a median age of 36 years (range 1-71 years); 60% were male. The analysis considered three time cohorts, 1980 to 1990, 1991 to 1999 and 2000 to 2003. Survival, transplant-related mortality and relapse incidence were assessed at 20 years for the first cohort and compared at 2 years between the three cohorts. The numbers of HSCT for CML increased from 540 allogeneic HSCT in 1990 to 1,396 HSCT in 1999 and declined to 802 in 2004. One third of all patients and half of those with a low risk were alive at 20 years. Survival at 2 years has improved from 53% to 61% in the most recent years due to a reduction in transplant-related mortality from 41% to 30% in all patients and from 31% to 17% in low-risk patients. Stage, donor type, time interval, age and donor-recipient sex combination remain the main risk factors; patients with a risk score of 0 or 1 have a survival probability of 80% at 2 years. HSCT remains an important treatment option for patients with CML. The data describe the current status of this option and the outcome a patient can expect today. They provide an objective basis for decision making.

KW - Chronic myeloid leukemia

KW - Europe

KW - Hematopoietic stem cell transplantation

KW - Long term results

KW - Outcome

KW - Transplant related mortality

UR - http://www.scopus.com/inward/record.url?scp=33646017748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646017748&partnerID=8YFLogxK

M3 - Article

C2 - 16533723

AN - SCOPUS:33646017748

VL - 91

SP - 513

EP - 521

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 4

ER -